Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Biemond

Showing results (191-200 of 255) with videos related to

Pageof 26
Sort By:
Haematologica|March 19, 2026
Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemiaBart J Biemond, Rachel Kesse-Adu, Ezanul Wahab, et al.
Critical Care Medicine|January 7, 2026
Minimal Gain in Prognostic Certainty for Patients With Hematologic Malignancies Over 2 Weeks of Intensive Care: An Analysis to Inform Time-Limited TrialsMartijn Otten, Brittney van der Woude, Bob J H van Kempen, et al.
Circulation|August 10, 2005
START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular diseaseNiels van Royen, Stephan H Schirmer, Bektas Atasever, et al.
Blood|September 14, 2017
Nonclassical <i>FCGR2C</i> haplotype is associated with protection from red blood cell alloimmunization in sickle cell diseaseSanne M Meinderts, Joep W R Sins, Karin Fijnvandraat, et al.
BMC Pediatrics|May 11, 2017
TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trialIrene L M Klaassen, Mandy N Lauw, Marianne D van de Wetering, et al.
Blood Advances|November 7, 2023
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label studyMyrthe J van Dijk, Minke A E Rab, Brigitte A van Oirschot, et al.
European Heart Journal|December 15, 2010
Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trialAlexander Hirsch, Robin Nijveldt, Pieter A van der Vleuten, et al.
The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.
Blood|January 12, 2019
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patientsGerwin Huls, Dana A Chitu, Violaine Havelange, et al.
American Journal of Hematology|September 4, 2025
Iron Deficiency in HbSC Disease Treated With Repetitive Phlebotomy Is Associated With Fewer Sickle Cell Disease-Related ComplicationsMarissa J M Traets, Aida S Kidane Gembremeskel, Jennifer Eijkelenboom-Bos, et al.
Pageof 26

Showing results (191-200 of 255) with videos related to

Sort By:
Pageof 26
Haematologica|March 19, 2026
Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemiaBart J Biemond, Rachel Kesse-Adu, Ezanul Wahab, et al.
Critical Care Medicine|January 7, 2026
Minimal Gain in Prognostic Certainty for Patients With Hematologic Malignancies Over 2 Weeks of Intensive Care: An Analysis to Inform Time-Limited TrialsMartijn Otten, Brittney van der Woude, Bob J H van Kempen, et al.
Circulation|August 10, 2005
START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular diseaseNiels van Royen, Stephan H Schirmer, Bektas Atasever, et al.
Blood|September 14, 2017
Nonclassical <i>FCGR2C</i> haplotype is associated with protection from red blood cell alloimmunization in sickle cell diseaseSanne M Meinderts, Joep W R Sins, Karin Fijnvandraat, et al.
BMC Pediatrics|May 11, 2017
TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trialIrene L M Klaassen, Mandy N Lauw, Marianne D van de Wetering, et al.
Blood Advances|November 7, 2023
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label studyMyrthe J van Dijk, Minke A E Rab, Brigitte A van Oirschot, et al.
European Heart Journal|December 15, 2010
Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trialAlexander Hirsch, Robin Nijveldt, Pieter A van der Vleuten, et al.
The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.
Blood|January 12, 2019
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patientsGerwin Huls, Dana A Chitu, Violaine Havelange, et al.
American Journal of Hematology|September 4, 2025
Iron Deficiency in HbSC Disease Treated With Repetitive Phlebotomy Is Associated With Fewer Sickle Cell Disease-Related ComplicationsMarissa J M Traets, Aida S Kidane Gembremeskel, Jennifer Eijkelenboom-Bos, et al.
Pageof 26